Drug Trial Radar · NCT06038474
Descartes-08 for Patients With Systemic Lupus Erythematosus
Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
6
Actual
Start
Feb 12, 2024
Primary completion
Dec 1, 2026
Study completion Dec 1, 2027
Sponsor
- Lead sponsor
- Cartesian TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Sep 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II study to evaluate the safety, tolerability and manufacturing feasibility of Descartes-08 CAR T-cells in patients with Systematic Lupus erythematosus (SLE).
Conditions
- Systemic Lupus Erythematosus (SLE)
Interventions
Descartes-08Drug
Autologous T-cells expressing a chimeric antigen receptor directed to BCMA
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess safety and tolerability of Descartes-08 in patients with systemic lupus erythematosus (SLE)Time frame: Day -59 to Day 50
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Profound Research LLC
Oceanside, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.